Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP)
Arch Bronconeumol. 2015 Apr;51(4):169-76.
doi: 10.1016/j.arbres.2014.09.019.
Epub 2015 Jan 29.
[Article in
English,
Spanish]
Authors
Pablo Sanchez-Salcedo
1
, Juan Berto
1
, Juan P de-Torres
1
, Arantzazu Campo
1
, Ana B Alcaide
1
, Gorka Bastarrika
2
, Jesús C Pueyo
2
, Alberto Villanueva
2
, José I Echeveste
3
, Maria D Lozano
3
, María J García-Velloso
4
, Luis M Seijo
5
, Javier García
6
, Wenceslao Torre
7
, Maria J Pajares
8
, Ruben Pío
8
, Luis M Montuenga
8
, Javier J Zulueta
9
Affiliations
- 1 Departamento de Neumología, Clínica Universidad de Navarra, Pamplona, España.
- 2 Departamento de Radiología, Clínica Universidad de Navarra, Pamplona, España.
- 3 Departamento de Anatomía Patológica, Clínica Universidad de Navarra, Pamplona, España.
- 4 Departamento de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, España.
- 5 Departamento de Neumología, IIS - Fundación Jiménez Díaz, CIBERES, Madrid, España.
- 6 Departamento de Neumología, Clínica Universidad de Navarra, Madrid, España.
- 7 Departamento de Cirugía Torácica, Clínica Universidad de Navarra, Pamplona, España.
- 8 Centro de Investigación Médica Aplicada - CIMA, Universidad de Navarra, Pamplona, España.
- 9 Departamento de Neumología, Clínica Universidad de Navarra, Pamplona, España. Electronic address: [email protected].
Abstract
Introduction and objectives:
European experience regarding lung cancer screening using low-dose chest CT (LDCT) is available. However, there is limited data on the Spanish experience in this matter. Our aim is to present the results from the longest ongoing screening program in Spain.
Methodology:
The Pamplona International Early Lung Cancer Detection Program (P-IELCAP) is actively screening participants for lung cancer using LDCT since year 2000 following the IELCAP protocol, including spirometric assessments. Men and women, ≥40 years of age, current or former smokers with a tobacco history of ≥10 pack-years are included. Results are compared to those from other European trials.
Results:
A total of 2989 participants were screened until March 2014 (73% male). A median of 2 (IQR 1-3) annual screening rounds were performed. Sixty lung cancers were detected in 53 participants (73% in StageI). Adenocarcinoma was the most frequent. The lung cancer prevalence and incidence proportion was 1.0% and 1.4%, respectively, with an annual detection rate of 0.41. The estimated 10-year survival rate among individuals with lung cancer was 70%. Chronic obstructive pulmonary disease and emphysema are important lung cancer predictors.
Conclusions:
The experience in Spain's longest lung cancer screening program is comparable to what has been described in the rest of Europe, and confirms the feasibility and efficacy of lung cancer screening using LDCT.
Keywords:
Chronic obstructive pulmonary disease; Cribado de cáncer de pulmón; Emphysema; Enfermedad pulmonar obstructiva crónica; Enfisema; España; LDCT; Lung cancer screening; Spain; TBDR.
Copyright © 2014 SEPAR. Published by Elsevier Espana. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / diagnostic imaging
-
Adenocarcinoma / epidemiology
-
Adult
-
Aged
-
Carcinoma, Non-Small-Cell Lung / diagnostic imaging
-
Carcinoma, Non-Small-Cell Lung / epidemiology
-
Early Detection of Cancer*
-
Feasibility Studies
-
Female
-
Humans
-
Incidence
-
Kaplan-Meier Estimate
-
Lung Neoplasms / diagnostic imaging*
-
Lung Neoplasms / epidemiology
-
Male
-
Middle Aged
-
Prevalence
-
Program Evaluation
-
Proportional Hazards Models
-
Pulmonary Disease, Chronic Obstructive / epidemiology
-
Pulmonary Emphysema / epidemiology
-
Risk
-
Smoking / adverse effects
-
Spain / epidemiology
-
Spirometry
-
Survival Rate
-
Tomography, X-Ray Computed / methods*